Acorda Therapeutics, Inc. focuses on developing therapies for neurological disorders, with its primary product being Inbrija, an inhaled formulation of levodopa for Parkinson's disease. The company operates primarily in the United States and has faced significant challenges in revenue generation and profitability.
Acorda generates revenue primarily through the sale of Inbrija, which is priced at approximately $1,500 per month for patients. The company has limited pricing power due to competition and the need for insurance coverage, impacting its revenue stability.
Regulatory approvals for new indications or products
Market penetration and sales growth of Inbrija
Partnerships or collaborations with larger pharmaceutical companies
Changes in reimbursement policies affecting drug pricing
Regulatory changes impacting drug approval processes
Technological advancements in competing therapies
Emergence of generic versions of Inbrija
New entrants in the Parkinson's disease treatment market
High operational losses leading to liquidity concerns
Potential need for additional financing to support R&D
low - Acorda's performance is less tied to the economic cycle as healthcare spending tends to be more stable.
Interest rates affect Acorda primarily through the cost of capital for funding R&D and operations, but the direct impact on demand is minimal.
minimal - Acorda's reliance on credit is low due to its negative cash flow and lack of significant debt.
growth - investors looking for potential turnaround opportunities in the biotech sector.
high - Acorda has exhibited significant stock price volatility, particularly due to operational challenges.